Search

Search Results

• Book

  Cancer symptom management. Fourth edition [4th ed.]

  edited by Connie Henke Yarbro, Debra Wujcik, Barbara Holmes Gobel.

  Contents:
  Evidence-based symptom management
  Artharalgias and myalgias
  Cancer-related fatigue
  Menopausal symptoms
  Pain
  Sleep disturbances
  Hypersensitivity reactions to antineoplastic drugs
  Infection
  Constipation
  Diarrhea
  Nausea and vomiting
  Malignant ascites
  Bladder disturbances
  Bleeding and thrombotic complications
  Dyspnea
  Effusions
  The cancer cachexia syndrome
  Dysphagia
  Mucositis
  Xerostomia
  Increased intracranial pressure
  Peripheral neuropathy
  Alopecia
  Altered body image and sexual health
  Extravasation
  Lymphedema
  Ocular and otic complications
  Skin and nail bed changes
  Anxiety
  Cognitive dysfunction
  Depression
  Grief
  Spiritual distress
  Symptoms when death is imminent.

  Print Access Request

  Location

  Version

  Call Number

  Items

  Books: General Collection (Downstairs)

  2014

  RC266 .C3564 2014

  1
  Get Shareable Link

  View Details
• Article

  Cell surface glycoproteins of murine cytotoxic T lymphocytes. I. T 145, a new cell surface glycoprotein selectively expressed on Ly 1-2+ cytotoxic T lymphocytes.

  Kimura AK, Wigzell H.

  J Exp Med. 1978 May 01;147(5):1418-34.

  T lymphocytes at various stages of maturation and differentiation have been isolated by cellular fractionation procedures and characterized by cell surface markers and functional assays, The cell surface glycoproteins of the various T-cell preparations have been selectively radiolabeled by the galactose oxidase-tritiated sodium borohydride technique and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and fluorography. Details are presented on the appearance of a new cell surface glycoprotein (T 145), present on immunocompetent T lymphocytes after activation by either major histocompatibility complex alloantigens or by concanavalin A. The intensity of T 145 expression on T lymphoblasts is shown to be directly correlated in time and extent to the levels of cytotoxicity generated in a variety of T-cell activations. Specific enrichment procedures of purified populations of mixed leukocyte culture blasts have shown Ly 1(+)2(-) blasts to be T 145(-) and Ly 1(-)2(+) blasts to be strongly T 145(+). Similar enrichment procedures on normal peripheral T cells have failed to reveal any significant expression of T 145 on a highly enriched population of Ly 1(-)2(+) T cells, Further studies on the stability of T 145 expression after induction have shown it to be a more permanent-type differentiation structure whose expression is clearly not linked to the blast stage of activation. T 145 would thus appear to represent a membrane glycoprotein whose exclusive expression on T lymphoblasts is further restricted to a defined group of cells endowed with cytolytic activity and bearing the Ly phenotype Ly 1(-)2(+).

  Digital Access Access Options
  Get Shareable Link

  PubMed